Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Jones, J. E.
  • Causey, C. P.
  • Knuckley, B.
  • Slack-Noyes, J. L.
  • Thompson, Paul

publication date

  • September 2009

journal

  • Current Opinion in Drug Discovery & Development  Journal

abstract

  • The protein arginine deiminases (PADs), and in particular PAD4, have emerged as potential therapeutic targets for the treatment of rheumatoid arthritis (RA). In this review, evidence linking dysregulated PAD activity to the onset and progression of RA is presented, and the potential role of such aberrant activity in other human diseases, such as multiple sclerosis and cancer, is discussed. The known physiological roles of the PADs, particularly PAD4, and current knowledge regarding PAD structure, catalysis and inhibition are also described.

subject areas

  • Animals
  • Antineoplastic Agents
  • Antirheumatic Agents
  • Arthritis, Rheumatoid
  • Catalysis
  • Drug Design
  • Drug Discovery
  • Enzyme Inhibitors
  • Humans
  • Hydrolases
  • Immunologic Factors
  • Isoenzymes
  • Models, Molecular
  • Molecular Structure
  • Multiple Sclerosis
  • Neoplasms
  • Protein Conformation
  • Structure-Activity Relationship
scroll to property group menus

Research

keywords

  • Cancer
  • PAD4
  • multiple sclerosis
  • protein arginine deiminase
  • protein arginine deiminase inhibitor
  • rheumatoid arthritis
scroll to property group menus

Identity

PubMed Central ID

  • PMC3771078

International Standard Serial Number (ISSN)

  • 1367-6733

PubMed ID

  • 19736621
scroll to property group menus

Additional Document Info

start page

  • 616

end page

  • 627

volume

  • 12

issue

  • 5

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support